{"entity":{"id":"nct02441309","kind":"trial","name":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","aka":["MEMOS"],"tldr":"A phase 2 trial of Mifamurtide and Ifosfamide in Osteosarcoma, run by University of Oxford, recorded as terminated on the registry.","summary":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) is a phase 2 interventional study registered as NCT02441309 by University of Oxford, with 8 participants recorded, started 2014-10 and due to reach its primary completion in 2016-11-04. Interventions recorded: Mifamurtide, Ifosfamide. Conditions recorded: Osteosarcoma.\n\nLinked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02441309","url":"https://clinicaltrials.gov/study/NCT02441309"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mifamurtide","ifosfamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02441309","phase":"2","setting":"A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma","sponsor":"University of Oxford","started":"2014-10","startedType":"actual","yearReported":2019,"enrolled":8,"enrolledBasis":"registry","outcomes":[{"endpoint":"Disease Specific Overall Survival","unit":"months","arms":[{"name":"A. Mifamurtide Only","n":3,"value":0.7,"note":"95% CI 0.2 to NA; Figures from the ClinicalTrials.gov results section (first posted 2019-09-13), not from a publication"},{"name":"B. Ifosfamide (Followed by Mifamurtide)","n":2,"value":9.2,"note":"95% CI 9.2 to NA"},{"name":"C. Ifosfamide + Mifamurtide","n":3,"value":2.8,"note":"95% CI 1.5 to NA"}],"source":"https://clinicaltrials.gov/study/NCT02441309?tab=results"},{"endpoint":"Progression Free Survival","unit":"months","arms":[{"name":"A. Mifamurtide Only","n":3,"note":"No events were observed, median is undefined.; Figures from the ClinicalTrials.gov results section (first posted 2019-09-13), not from a publication"},{"name":"B. Ifosfamide (Followed by Mifamurtide)","n":2,"note":"No events were observed, median is undefined."},{"name":"C. Ifosfamide + Mifamurtide","n":3,"value":7,"note":"95% CI 4.6 to NA"}],"source":"https://clinicaltrials.gov/study/NCT02441309?tab=results"}]},"route":"/trials/nct02441309/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/"},{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/"}]}}